Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Home

emcure pharma

Tag: emcure pharma

Read all Latest developments, information and news on and about emcure pharma - Page 2

Emcure Pharma is an Indian pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules, and injectables.

Emcure wins dismissal of US lawsuit over COVID vaccine trade secrets

Ruchika Sharma7 Dec 2023 2:42 PM IST

The lawsuit said that HDT licensed its technology to Emcure subsidiary Gennova Biopharmaceuticals to develop and sell the vaccine in India. HDT...

CDSCO Drug Alert: 61 Drug Samples Including Emcure's Levocarnitine Inj Flagged

Dr. Divya Colin24 Nov 2023 6:00 PM IST

New Delhi: In its latest drug alert, the apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO), has flagged 61 medicine...

Emcure Pharma Expands Its Dermatology Portfolio

Emcure Pharma aims to raise USD 400- USD 500 million from IPO planned for next year

Ruchika Sharma26 Sept 2023 2:34 PM IST

India's pharmaceuticals market is expected to reach USD 130 billion in 2030 from USD 50 billion currently, and deal-making in the sector is booming.

Emcure gets CDSCO Panel Nod To Manufacture, Market ferric Carboxymaltose injection 50mg/ml

Dr. Divya Colin25 Sept 2023 6:00 PM IST

New Delhi: Emcure Pharmaceuticals has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...

Emcure Pharmaceuticals Gets CDSCO To Manufacture & Market the FDC Antiviral Drug

Dr. Divya Colin4 May 2023 6:00 PM IST

New Delhi: Granting approval for bioequivalence (BE) study and clinical trial (CT) study waiver, the Subject Expert Committee (SEC) functional under...

Emcure Pharma wins Merit Award at HIV Congress 2023

Ruchika Sharma9 April 2023 10:00 AM IST

Pune: Emcure Pharmaceuticals, a Indian pharmaceutical company, has been felicitated for its contributions to HIV/AIDS research and development at the...

Patient dies from suspected drug reaction to Emcure Pharma Orofer FCM, Maha FDA issues nationwide recall

Roshni Dhar25 Nov 2022 5:37 PM IST

Drug maker Emcure Pharmaceuticals Ltd. has landed in trouble after a patient at Saifee Hospital administered iron supplement, Orofer FCM (ferric...

Health Bulletin 25/November/2022

Roshni Dhar25 Nov 2022 4:51 PM IST

Here are the top health news for the day:Thirteen measles deaths reported in Mumbai An eight-year-old boy from Govandi died on Thursday due to...

Patient dies from suspected drug reaction to Emcure Pharma's Orofer FCM, Maha FDA issues nationwide recall

Farhat Nasim24 Nov 2022 5:48 PM IST

Pune: Drug maker Emcure Pharmaceuticals Ltd. has landed in trouble after a patient at Saifee Hospital administered iron supplement, Orofer FCM (ferric...

HC restrains pharma companies from infringing Boehringer Ingelheim diabetes drug Linagliptin

Susmita Roy8 Jun 2022 4:04 PM IST

New Delhi: In a major relief to pharmaceuticals major Boehringer Ingelheim, the High Court has restrained four domestic pharma companies namely,...

NPPA fixes price of 84 formulations, revises 1

Ruchika Sharma13 May 2022 3:00 PM IST

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 84 formulations and has...

Ahead of Linagliptin going off-patent, NPPA fixes retail price of its FDC with Metformin

Susmita Roy20 April 2022 6:57 PM IST

New Delhi: With the popular antidiabetic drug Linagliptin soon expected to go off-patent, the apex drug price regulator, National Pharmaceutical...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok